

Regulation of Sphingosine Kinase by Interacting Proteins

Tamara Marie Leclercq

School of Molecular and Biomedical Science, Discipline of Biochemistry

The University of Adelaide

February 2010

Declaration by Author

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Tamara Marie Leclercq and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (listed below) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Leclercq,T.M. & Pitson,S.M. (2006). Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. *IUBMB Life*. 2006. 58, 467-472. Review

Leclercq,T.M., Moretti,B.B., Vadas,M.A. and Pitson,S.M. (2008). Eukaryotic elongation Factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. *J. Biol. Chem.* 2008. 283, 9606-9614

Tamara Leclercq

Acknowledgements

First thanks must go to my supervisor, Dr Stuart Pitson. Thank you for giving me the opportunity to work and study in your laboratory. Your role as my early career mentor will forever be appreciated and your tireless efforts towards my projects, and of course in this thesis, will not be forgotten.

Secondly to my wonderful parents. They say you can't choose your family, but I couldn't have chosen any better anyway. This thesis symbolizes the culmination of many years of study, through which your unwavering love and support have seen me through. Mum, thanks for all the dinners, and dad, thanks for all the scrabble and yahtzee challenges, they were welcome breaks. I love you both very much.

I would also like to thank all my family and friends. Although you may think you have not played a role in this achievement, time spent together having fun and relaxing have kept me sane! Particular thanks to the girls in the laboratory (you know who you are), I'm sure science is sending us mad, but working with you has been an absolute pleasure.

I could not complete this acknowledgements page without mentioning my wonderful husband. You proposed to me at the beginning of my Phd and I wonder if you knew what you were getting yourself into! Whenever I needed to talk or needed someone to encourage me to keep going, you were always there. Your ability to make me laugh in any situation has saved me from destroying my laptop on several occasions! You are truly my better half, and I thank and love you for loving me.

Last but by no means least, I would like to thank you, the examiners. I know examining this thesis must be an arduous task and I genuinely appreciate it. Regular red wine breaks are highly recommended!

Abstract

Sphingosine kinase 1 (SK1) is responsible for phosphorylating the lipid sphingosine, generating the bio-active phospholipid, sphingosine 1-phosphate (S1P). Cells possess basal SK1 activity which has been proposed to serve in a 'housekeeping' function to limit the levels of pro-apoptotic sphingosine and ceramide in the cell. In some circumstances, however, such as cell exposure to growth factors and cytokines this basal level of SK1 activity is increased, resulting in an increased production of S1P. As S1P is a pro-proliferative, pro-survival molecule, its increased production is associated with enhanced cell proliferation, survival and an oncogenic phenotype.

The Pitson laboratory has shown previously that one mechanism by which SK1 is activated is through phosphorylation at Ser-225 by ERK1/2. Here, my studies focused on alternative mechanisms of SK1 activation that arise through its interaction with two proteins, eukaryotic elongation factor 1A (eEF1A) and a relatively uncharacterised protein, SK activator molecule 1 (SKAM). eEF1A is able to directly increase the catalytic activity of SK1 *in vitro* and is also able to increase endogenous SK activity when over-expressed in quiescent cells that have reduced levels of endogenous eEF1A protein. Due to the abundance of eEF1A protein within a cell, I hypothesized that the effect of eEF1A on SK activity may be dynamically regulated. eEF1A contains a 'G protein-like' domain that enables it to bind GDP and GTP. When bound by GTP, eEF1A undergoes a large conformational change that enables it to bind aminoacyl-tRNA for transport to the ribosome. Similarly, just as the nucleotide-bound state of eEF1A regulates its role in protein synthesis, I found that the nucleotide-bound state of eEF1A also regulates its ability to activate SK1. Strikingly, it is only the translationally inactive eEF1A.GDP that can activate SK1. A truncated form of eEF1A named PTI-1 has been described that lacks the 'G protein-like' domain and thus can not bind guanine nucleotides, rendering it structurally analogous to eEF1A.GDP. In keeping with my finding that only eEF1A.GDP activates SK1, I found that PTI-1 also activates SK1 both *in vitro* and in cells. Importantly, PTI-1 has been previously characterized as an oncoprotein and for the first time my studies have shown a likely mechanism by which PTI-1 induces a tumourigenic phenotype. Expression of PTI-1 in NIH 3T3 cells induces neoplastic transformation, as measured by focus formation. Notably, this PTI-1-induced transformation is blocked when cells are treated with

SK inhibitors or when cells are co-transfected with PTI-1 and a dominant negative SK1, indicating that oncogenesis by PTI-1 is mediated through SK1.

The current study also investigated the regulation of SK1 activity by its interaction with SKAM1. Previous studies have shown that SKAM1, like eEF1A, can directly increase the catalytic activity of SK1 *in vitro* and in cells. My studies have determined the minimal region of interaction of SKAM1 that is still able to interact with and activate SK1. Remarkably, a 35 amino acid SKAM1 peptide retained the ability to activate SK1. The physiological relevance of the SK1-SKAM1 interaction was also examined and I have shown that knock-down of SKAM1, and the related protein SKAM2, in HEK 293T cells resulted in decreased cell proliferation coupled with increased susceptibility to apoptosis. Results presented here, also suggest that phosphorylation of SKAM1 at Tyr-46 acts as a negative regulator for SKAM1-induced SK1 activation.

In summary, the current study presents two novel SK1 interacting proteins that directly increase the catalytic activity of this enzyme, and investigates mechanisms by which their effects on SK1 activity are regulated. While the guanine nucleotide bound state of eEF1A1 determines its effects on SK1 activity, the phosphorylation status of SKAM1 appears to determine its ability to activate SK1.

Table of Contents

Declaration by Author.....	2
Acknowledgements.....	3
Abstract.....	4
Table of Contents.....	6
List of Figures.....	10
List of Tables.....	13
List of Abbreviations.....	14
1. Introduction.....	17
1.1 SK and S1P in cellular signaling.....	18
1.1.1 Extracellular functions of S1P.....	20
1.1.2 Intracellular functions of S1P.....	23
1.2 Isoforms and biochemistry of the SKs.....	24
1.3 Disease development linked to SK and S1P.....	29
1.3.1 Cancer.....	29
1.3.2 Inflammation and hypertension.....	31
1.4 SK1 activation by phosphorylation.....	32
1.5 SK interacting proteins.....	33
1.5.1 TRAF2.....	34
1.5.2 RPK118.....	34
1.5.3 SKIP.....	34
1.5.4 δ -catenin.....	35
1.5.5 Aminoacylase 1.....	35
1.5.6 PECAM and $\alpha_v\beta_3$	36
1.5.7 Calmodulin.....	36
1.5.8 CIB1.....	37
1.5.9 Lyn and Fyn kinases.....	37
1.5.10 Filamin A.....	38
1.5.11 FHL-2/SLIM3.....	39

1.6 Novel SK1-interacting proteins.....	40
1.6.1 eEF1A.....	40
1.6.1.1 Involvement of eEF1A in disease.....	46
1.7 Aims of the thesis.....	49
2. Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity.....	50
2.1 Summary.....	51
2.2 Introduction.....	51
2.3 Materials and Methods.....	53
2.3.1 Cell culture and transfection.....	53
2.3.2 Yeast two-hybrid screen.....	54
2.3.3 Cloning of eEF1A1 and eEF1A2.....	54
2.3.4 Generation of GST-fusion proteins.....	54
2.3.5 Sphingosine kinase assays.....	55
2.3.6 <i>In vitro</i> phosphorylation of SK1 and eEF1A1.....	56
2.3.7 Immunoprecipitation and immunoblotting.....	56
2.3.8 GST-fusion protein binding analyses.....	57
2.3.9 Lipid determinations.....	57
2.4 Results.....	58
2.4.1 eEF1A1 is a SK1 interacting and activating protein.....	58
2.4.2 eEF1A1 interacts with and enhances SK2 activity.....	62
2.4.3 eEF1A2 is a SK1 interacting and activating protein.....	62
2.4.4 The interaction of SK1 with eEF1A1 is not regulated by phosphorylation.....	67
2.4.5 eEF1A1 over-expression in quiescent cells enhances endogenous SK1 activity.....	70
2.4.6 siRNA-mediated down regulation of eEF1A2 decreases endogenous SK1 activity and S1P levels.....	74
2.5 Discussion.....	74
3. Guanine nucleotides regulate sphingosine kinase 1 activation by eEF1A: a mechanism for eEF1A-associated oncogenesis.....	82
3.1 Summary.....	83
3.2 Introduction.....	83

3.3	Materials and Methods.....	85
3.3.1	Cell culture, transfection and focus formation assays.....	85
3.3.2	Generation of TCTP and PTI-1 expression constructs.....	85
3.3.3	GST pull-down assays.....	86
3.3.4	Generation of recombinant T7-eEF1A1.....	86
3.3.5	Quantitation of GDP associated with ectopically expressed eEF1A1 and eEF1A2.....	87
3.3.6	Nucleotide loading of eEF1A1.....	87
3.4	Results.....	88
3.4.1	GDP-bound eEF1A1 selectively activates SK1.....	88
3.4.2	TCTP expression modulates SK1 activity.....	89
3.4.3	Expression of eEF1A2 enhances SK1 activity.....	93
3.4.4	PTI-1-induced oncogenesis is dependent on SK1 activity.....	96
3.5	Discussion.....	100
4.	Sphingosine kinase activator molecule 1 (SKAM1): activation of SK1 and its regulation by SKAM1 phosphorylation.....	103
4.1	Summary.....	104
4.2	Introduction.....	104
4.3	Materials and Methods.....	111
4.3.1	Generation of the SKAM expression constructs.....	111
4.3.2	Effect of SKAM1 and eEF1A1 on SK1 activity <i>in vitro</i>	113
4.3.3	GST pull-down assays.....	114
4.3.4	Generation of cells expressing SKAM1 and -2 antisense constructs.....	115
4.3.5	Growth rate assay.....	115
4.3.6	DAPI staining for apoptosis.....	116
4.3.7	Immunoprecipitation of SKAM1A for determination of its tyrosine phosphorylation status.....	116
4.3.8	<i>In vitro</i> phosphorylation of GST-SKAM1D, GST-SKAM1D ^{Y46F} , GST-SKAM1D ^{Y104F} and GST-SKAM1D ^{Y46F/Y104F} using recombinant EphB1 kinase.....	116
4.4	Results.....	117
4.4.1	SKAM1 and eEF1A1 have no additive effect on SK1 activity <i>in vitro</i>	117
4.4.2	SKAM1 and eEF1A1 bind SK1 at the same site <i>in vitro</i>	117

4.4.3	The addition of SKAM1A and SKAM1C has no additive effect on the activity of SK1 <i>in vitro</i>	120
4.4.4	Cells co-transfected with SKAM1A and SKAM2 antisense have a reduced ability to grow and increased susceptibility to serum deprivation-induced apoptosis.....	120
4.4.5	Peptides of SKAM1 retain the ability to interact with and activate SK1 <i>in vitro</i>	122
4.4.6	SKAM1A is tyrosine phosphorylated.....	126
4.4.7	SKAM1A ^{Y46F} has an increased ability to activate endogenous SK1 compared to wild-type SKAM1A.....	126
4.4.8	GST-SKAM1D, GST-SKAM1D ^{Y46F} , GST-SKAM1D ^{Y104F} and GST-SKAM1D ^{Y46F/Y104F} can be tyrosine phosphorylated <i>in vitro</i> by EphB1 kinase.....	130
4.5	Discussion.....	133
5	General Discussion.....	138
5.1	eEF1A as a SK activator.....	140
5.1.1	eEF1A and its nucleotide-bound state.....	140
5.1.2	Post-translational modification of eEF1A1.....	141
5.1.3	Activation of SK1 by eEF1A2.....	143
5.1.4	Cancer, SK1 and eEF1A.....	144
5.1.4.1	eEF1A2 in cancer.....	145
5.1.4.2	TCTP.....	146
5.1.4.3	PTI-1.....	147
5.2	SKAM1 as a SK1 activator.....	148
5.2.1	SKAM1 and phosphorylation.....	149
5.2.2	Wound healing versus cancer: SK1 and SKAM1.....	149
5.3	eEF1A and SKAM1: friends of foes?.....	151
5.4	Conclusions, significance and future directions.....	155
6	References.....	158
7	Appendices.....	181

List of Figures

Chapter 1

<i>Figure 1.1</i> The sphingomyelin cycle.....	19
<i>Figure 1.2</i> Regulation and function of sphingosine kinases.....	22
<i>Figure 1.3</i> Sphingosine kinases are conserved across a diverse range of eukaryotic organisms.....	26
<i>Figure 1.4</i> Sequence alignment of human EF1A1 and EF1A2.....	41
<i>Figure 1.5</i> eEF1A in translational elongation.....	42
<i>Figure 1.6</i> Structures of bacterial EF1A bound by GTP or GDP.....	43
<i>Figure 1.7</i> A schematic representation of the human eEF1A1 and PTI-1 transcripts.....	48

Chapter 2

<i>Figure 2.1</i> eEF1A1 interacts with SK1.....	60
<i>Figure 2.2</i> eEF1A1 enhances SK1 activity <i>in vitro</i>	61
<i>Figure 2.3</i> SK1 is stable under the conditions of the <i>in vitro</i> SK activity assay.....	63
<i>Figure 2.4</i> eEF1A1 enhances SK1 activity <i>in vitro</i>	64
<i>Figure 2.5</i> eEF1A1 interacts with and activates SK2 <i>in vitro</i>	66
<i>Figure 2.6</i> eEF1A2 interacts with SK1 and increases its activity <i>in vitro</i>	68
<i>Figure 2.7</i> Phosphorylation of SK1 does not alter binding to eEF1A1.....	69
<i>Figure 2.8</i> Phosphorylation of eEF1A1 does not alter binding to, or activation of, SK1 or SK2 <i>in vitro</i>	71
<i>Figure 2.9</i> Over-expression of eEF1A1 in proliferating cells has no effect on endogenous SK activity.....	72
<i>Figure 2.10</i> Over-expression of eEF1A1 in quiescent cells increases endogenous SK1 activity.....	73
<i>Figure 2.11</i> siRNA-mediated down regulation of eEF1A2 in MCF7 cells decreases endogenous SK1 activity and S1P levels.....	75

<i>Figure 2.12</i> siRNA-mediated down regulation of eEF1A2 in MCF7 cells does not alter cellular sphingosine levels.....	76
<i>Figure 2.13</i> Bacterial EF1A, EF-Tu, interacts with SK1.....	81
Chapter 3	
<i>Figure 3.1</i> Guanine nucleotides regulate the effect of eEF1A1 on SK1 activity.....	90
<i>Figure 3.2</i> TCTP expression regulates cellular SK1 activity in quiescent CHO cells.....	91
<i>Figure 3.3</i> Association of eEF1A1 and eEF1A2 with GDP in cells.....	92
<i>Figure 3.4</i> TCTP knock-down decreases cellular SK1 activity.....	94
<i>Figure 3.5</i> TCTP expression regulates cellular SK1 activity in proliferating CHO cells.....	95
<i>Figure 3.6</i> PTI-1 interacts with and activates SK1 <i>in vitro</i>	97
<i>Figure 3.7</i> PTI-1 activates SK1 in cells.....	98
<i>Figure 3.8</i> Inhibition of SK1 ablates PTI-1-induced neoplastic transformation.....	99
Chapter 4	
<i>Figure 4.1</i> SKAM1 isoforms.....	105
<i>Figure 4.2</i> All naturally occurring SKAM1 isoforms interact with SK1.....	106
<i>Figure 4.3</i> All SKAM1 isoforms activate SK1 in cells and <i>in vitro</i>	108
<i>Figure 4.4</i> SKAM1D activates SK1 in a dose dependent manner <i>in vitro</i>	109
<i>Figure 4.5</i> SKAM1 and eEF1A1 may activate SK1 by a common mechanism <i>in vitro</i>	118
<i>Figure 4.6</i> SKAM1D and eEF1A1 bind SK1 at a common site <i>in vitro</i>	119
<i>Figure 4.7</i> SKAM1A together with SKAM1C has no additive effect on SK1 activity <i>in vitro</i>	121
<i>Figure 4.8</i> Cells transfected with SKAM1A antisense and SKAM2 antisense exhibit decreased cell growth.....	123
<i>Figure 4.9</i> Cells transfected with SKAM1A antisense and SKAM2 antisense exhibit increased cell apoptosis.....	124
<i>Figure 4.10</i> Sequence alignment of SKAM1B and SKAM2.....	125

<i>Figure 4.11</i> SKAM1 peptides retain the ability to interact with SK1 <i>in vitro</i>	127
<i>Figure 4.12</i> SKAM1 peptides retain the ability to activate SK1 <i>in vitro</i>	128
<i>Figure 4.13</i> SKAM1A is tyrosine phosphorylated.....	129
<i>Figure 4.14</i> SKAM1A ^{Y46F} has an enhanced ability to activate endogenous SK1 compared to wild-type SKAM1A.....	131
<i>Figure 4.15</i> Wild-type SKAM1D and SKAM1D ^{Y46F} are phosphorylated by EphB1 kinase <i>in vitro</i>	132
<i>Figure 4.16</i> SKAM1DY ^{104F} and SKAM1D ^{Y46F/Y104F} are phosphorylated by EphB1 kinase <i>in vitro</i>	134
 Chapter 5	
<i>Figure 5.1</i> Region of high sequence similarity between eEF1A1, eEF1A2, SKAM1 and SKAM2.....	153

List of Tables

Chapter 2

Table 2.1 Substrate kinetics of SK1 in the presence of eEF1A1 *in vitro*.....65

Chapter 4

Table 4.1 Enzyme kinetics of SK1 in the presence of SKAM1D *in vitro*.....110

List of Abbreviations

AAD	adult atopic dermatitis
AC	adenylyl cyclase
AML	acute myeloid leukaemia
aa-tRNA	aminoacyl-transfer ribonucleic acid
Acy1	aminoacylase 1
BMDC	bone marrow-derived mast cells
BrdU	bromodeoxyuridine
CDP	calcium dependent protein
Cer	ceramide
CHO	Chinese hamster ovarian
CIB1	calcium and integrin binding protein 1
DAPI	4'-6-Diamidino-2-phenylindole
DMS	dimethyl-sphingosine
eEF1A	eukaryotic elongation factor 1A
eEF1B	eukaryotic elongation factor 1B
EGF	epidermal growth factor
EPG	ethanolamine-phosphoglycerol
ER	endoplasmic reticulum
ERK	extracellularly regulated kinase
FBS	foetal bovine serum
FGFR1	fibroblast growth factor receptor 1
FGFR1OP2	fibroblast growth factor receptor 1 oncogenic partner 2
FHL2	four-and-a-half LIM only protein-2
FLNa	Filamin A
GAP	GTPase-activating protein
GDP	guanine di-phosphate
GDI	guanine nucleotide dissociation inhibitor

GEF	guanine nucleotide exchange factor
GPCR	G-protein coupled receptors
GSH	glutathione
GST	glutathione- <i>s</i> -transferase
GTP	guanine tri-phosphate
HA	haemmagglutinin
HDAC1/HDAC2	histone deacetylase 1 / histone deacetylase 2
HDL	high density lipoprotein
HEK	human embryonic kidney
Hrg	heregulin
HuMC	human peripheral blood-derived mast cells
FcεRI	immunoglobulin E
MS	mass-spectrometry
MTS	3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
PAK1	p21-activated kinase 1
PECAM-1	platelet endothelial cell adhesion molecule 1
PI4K	phosphatidylinositol 4-kinase
PKC	protein kinase C
PKD	protein kinase D
PLCγ	phospholipase Cγ
PMS	phenazine methosulfate
PP2A	protein phosphatase 2A
Prdx-I	peroxiredoxin I
PTI-1	prostate tumour inducer-1
rSK or rec-SK	purified recombinant SK
TCTP	translationally controlled tumour protein
TNF-α	tumour necrosis factor α
TRAF2	TNFα receptor associated factor 2

SK	sphingosine kinase
SKAM	sphingosine kinase activator molecule
SKIP	sphingosine kinase interacting protein
S1P	Sphingosine 1-phosphate
S1P ₁₋₅	sphingosine 1-phosphate receptors 1-5
S1PL	sphingosine 1-phosphate lyase
S1PP	sphingosine 1-phosphate phosphatase
Sph	sphingosine
VECAM-1	vascular cell adhesion molecule-1
VEGF	vascular endothelial growth factor
VEGFR2	vascular endothelial growth factor receptor 2
Wit3.0	wound inducible transcript 3.0